Literature DB >> 2473860

Histamine release from basophils in cystic fibrosis.

W Schönfeld1, A Saak, G Steinkamp, H Van der Hardt, W König.   

Abstract

We determined the histamine release from basophils in patients suffering from cystic fibrosis (CF) (median 17.2 years of age) and compared the data with an age-matched group of healthy donors. No significant differences in the basophil counts were determined between the CF and control groups. However, the absolute histamine content per basophil was elevated in the CF group (2.6 +/- 0.4 pg/basophil versus 1.4 +/- 0.2, mean +/- s.e.m., n = 15/10, P less than 0.004). Stimulation of basophils with the Ca ionophore (7.5 microM) and anti-IgE (10(-2) of a stock preparation) leads to a significantly higher release of histamine per basophil in CF patients as compared to healthy donors (Ca ionophore: 1.6 +/- 0.2 versus 0.9 +/- 0.2, mean +/- s.e.m., P less than 0.008; anti-IgE: 0.45 +/- 0.007 versus 0.28 +/- 0.04, P less than 0.02). These data indicate that basophils in CF may have a greater potential to release mediators although their releasability, expressed as the percentage of histamine release of the total histamine content, does not differ significantly compared to the healthy donors (62.1 +/- 8.3% versus 60.2 +/- 13%, mean +/- s.e.m.). Within the 14-day period of intravenous antibiotic treatment of the pulmonary infection (in 14 out of 15 cases P. aeruginosa was isolated from sputa samples) histamine release per basophil and total histamine content decreased to normal levels (day 1 2.6 +/- 0.3 versus 1.8 +/- 0.3, P less than 0.05). This decline was accompanied by an improvement of the clinical condition of the patient and reduction of P. aeruginosa isolates in sputa (n = 8). In contrast, in three patients with sustained P. aeruginosa colonization of the upper airways and impaired lung function histamine levels remained elevated. Our data demonstrate that the histamine content of basophils, as well as the release of histamine, is increased in patients with cystic fibrosis and correlates with the clinical signs of the chronic infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473860      PMCID: PMC1541905     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  J T Zakrzewski; N C Barnes; J F Costello; P J Piper
Journal:  Am Rev Respir Dis       Date:  1987-09

3.  The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors:  A R Chrispin; A P Norman
Journal:  Pediatr Radiol       Date:  1974

Review 4.  Inflammation--histamine and 5-hydroxytryptamine.

Authors:  D A Owen
Journal:  Br Med Bull       Date:  1987-04       Impact factor: 4.291

5.  In vitro effect of the slime of Pseudomonas aeruginosa on the function of human polymorphonuclear neutrophils.

Authors:  P F Laharrague; J X Corberand; G Fillola; B J Gleizes; A M Fontanilles; E Gyrard
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

6.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-12       Impact factor: 3.791

7.  Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.

Authors:  G Döring; N Høiby
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

Review 8.  IgE-binding factors and regulation of the IgE antibody response.

Authors:  K Ishizaka
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

9.  Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3.

Authors:  C A Smith; D M Rennick
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

Review 10.  B-cell stimulatory factor-1/interleukin 4.

Authors:  W E Paul; J Ohara
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

View more
  2 in total

1.  Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes.

Authors:  B König; K E Jaeger; A E Sage; M L Vasil; W König
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 2.  Immunomodulation in Cystic Fibrosis: Why and How?

Authors:  Vincent D Giacalone; Brian S Dobosh; Amit Gaggar; Rabindra Tirouvanziam; Camilla Margaroli
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.